• Subscribe
  • Webinars
  • White Papers
  • Buyer's Guide
  • PhotonicsNXT
  • Get Published!
    • Recent Quotes
    My Watchlist
    Indicators
    LFW Photonics Market Index
    Markets
    Stocks
    ETFs
    Tools
    Overview
    News
    Currencies
    International
    Treasuries

    Pyxis Oncology, Inc. - Common Stock (NQ: PYXS )

    1.600 UNCHANGED
    Streaming Delayed Price Updated: 1:00 PM EST, Dec 24, 2024 Add to My Watchlist
    Quote
    Overview Detailed Quote Charting Historical Prices
    News
    All News News Headlines Press Releases
    Research
    Quarterly Reports Insider Filings Other Filings

    Headline News about Pyxis Oncology, Inc. - Common Stock

    < Previous 1 2 3 Next >
    Pyxis Oncology's Deprioritizes Second Pipeline Asset, Analyst Applauds Move
    Pyxis Oncology prioritizes PYX-201 with promising Phase 1 results in solid tumors, while deprioritizing PYX-106 due to resource allocation and challenges. 
    Via Benzinga
    12 Health Care Stocks Moving In Thursday's Pre-Market Session
    Via Benzinga
    Nasdaq Edges Higher; Baidu Shares Fall After Q3 Results
    Via Benzinga
    Crude Oil Gains 1%; Deere Posts Better-Than-Expected Earnings
    Via Benzinga
    Exposures Fossil Fuels
    Dow Jumps Over 100 Points; Nvidia Posts Upbeat Earnings
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Pyxis Oncology: Q4 Earnings Insights
    Via Benzinga
    Pyxis Oncology's Cancer Drug Progress Stirs Analyst Concerns
    Pyxis Oncology announces mixed Phase 1 PYX-201 data, collaboration with Merck, and analyst downgrade citing limited efficacy beyond head-and-neck cancer. 
    Via Benzinga
    Pyxis Oncology's Cancer Drug Platform Shows Potential, Analyst Sees Over 190% Upside
    Stephens initiates coverage on Pyxis Oncology (PYXS), highlighting its promising ADC technology and a $13 price target, with upcoming clinical trial results. 
    Via Benzinga
    PYXS Stock Earnings: Pyxis Oncology Misses EPS for Q2 2024
    PYXS stock results show that Pyxis Oncology missed analyst estimates for earnings per share the second quarter of 2024. 
    Via InvestorPlace
    PYXS Stock Earnings: Pyxis Oncology Beats EPS, Beats Revenue for Q1 2024
    PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share and beat on revenue for the first quarter of 2024. 
    Via InvestorPlace
    Signet Jewelers, Dave & Buster's Entertainment, Blue Owl Capital And Other Big Stocks Moving Higher On Wednesday
    U.S. stocks were higher, with the Dow Jones gaining over 50 points on Wednesday. 
    Via Benzinga
    Topics Stocks
    Exposures US Equities
    Why Ulta Beauty Shares Are Trading Lower By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
    Shares of Ulta Beauty, Inc. (NASDAQ: ULTA) fell sharply during Wednesday’s session amid the company's presentation at the J.P. Morgan Retail Roundup investor conference where the company reportedly... 
    Via Benzinga
    Exposures Glyphosate
    3 Biotech Stocks to Buy on the Dip: March 2024
    Some of the best opportunities can be found in dips in some of the top biotech stocks to buy. In fact, here are three. 
    Via InvestorPlace
    Why FedEx Shares Are Trading Higher By Around 12%; Here Are 20 Stocks Moving Premarket
    Shares of FedEx Corporation (NYSE: FDX) rose sharply in today’s pre-market trading after the company reported better-than-expected earnings for its third quarter and authorized a new $5 billion 
    Via Benzinga
    Why FactSet Research Shares Are Trading Lower By Around 5%? Here Are Other Stocks Moving In Thursday's Mid-Day Session
    Shares of FactSet Research Systems Inc. (NYSE: FDS) fell sharply during Thursday’s session after the company reported worse-than-expected second-quarter revenue and issued FY24 guidance. 
    Via Benzinga
    PYXS Stock Earnings: Pyxis Oncology Beats EPS for Q4 2023
    PYXS stock results show that Pyxis Oncology beat analyst estimates for earnings per share the fourth quarter of 2023. 
    Via InvestorPlace
    From Six Figures to Seven: 3 Biotech Stocks Set to Make Millionaires
    These biotech stocks to buy offer a gateway to long-term gains, on the back of groundbreaking healthcare innovations. 
    Via InvestorPlace
    Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Friday
    It's time to start the final day of trading this week with a look into the biggest pre-market stock movers for Friday morning! 
    Via InvestorPlace
    3 Biotech Stocks to Turn $10,000 Into $1 Million: February 2024
    With new innovation and high demand, biotech stocks could offer some of the most explosive opportunities of the year. 
    Via InvestorPlace
    12 Health Care Stocks Moving In Friday's After-Market Session
    Via Benzinga
    Why Helix Energy Solutions Shares Are Trading Lower By 11%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Shares of Helix Energy Solutions Group, Inc. (NYSE: HLX) fell sharply during Tuesday’s session following weak earnings. 
    Via Benzinga
    Pyxis Oncology M&A Spotlight Signals Potential Growth Amidst Competitive ADC Landscape: Analyst
    RBC Capital Markets has initiated coverage on Pyxis Oncology Inc (NASDAQ: PYXS) with an Outperform rating and a  
    Via Benzinga
    Small SPAC Biotech Apexigen To Be Acquired Pyxis Oncology For $16M
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For September 5, 2023
    Via Benzinga
    Pyxis Oncology Bolsters Oncology Portfolio Through $16M Apexigen Acquisition
    Pyxis Oncology (NASDAQ:PYXS) has announced an acquisition of Apexigen (NASDAQ:APGN) that is expected to be completed in the second half of 2023. 
    Via Benzinga
    Benzinga's Top Ratings Upgrades, Downgrades For July 31, 2023
    Via Benzinga
    Why Is Apexigen (APGN) Stock Up 31% Today?
    Apexigen (APGN) stock is rising higher on Wednesday following news of a $16 million acquisition deal with Pyxis Oncology (PYXS). 
    Via InvestorPlace
    Why Chicken Soup For The Soul Entertainment Shares Are Trading Higher By 14%; Here Are 20 Stocks Moving Premarket
    Gainers RiceBran Technologies (NASDAQ: RIBT) gained 43.1% to $1.33 in pre-market trading after gaining 3% on Tuesday. 
    Via Benzinga
    Why Bullfrog AI Holdings Shares Are Trading Higher By 73%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
    Gainers Secoo Holding Limited (NASDAQ: SECO) shares surged 138% to $1.43. 
    Via Benzinga
    12 Health Care Stocks Moving In Monday's Pre-Market Session
    Via Benzinga
    < Previous 1 2 3 Next >
    Stock Quote API & Stock News API supplied by www.cloudquote.io
    Quotes delayed at least 20 minutes.
    By accessing this page, you agree to the following
    Privacy Policy and Terms and Conditions.